Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our vision...

A trusted advisor transforming patients’ lives worldwide with pioneering molecular diagnostics

The global leader in personalized medicine
Myriad Leads Personalized Medicine Industry
Unique Scale and Expertise Creates Sustainable Competitive Advantage

Over 27 years since company was founded in 1991

1 only profitable R&D driven personalized medicine company

✓ >3.0 million tests performed; unmatched reputation for quality

2,500 employees dedicated to the Myriad mission

>1,000 scientific publications to date; extensive research capabilities

3 expertise with all three types of biomarkers (DNA, RNA, and proteins)

1 only personalized medicine company with broad regulatory experience

>90,000 ordering physicians since inception; deep relationships

95% of U.S. payers are in-network
Myriad’s 4 in 6 Strategy

Answering patients’ four most pressing questions

Will I get a disease?
Do I have a disease?
Should I treat this disease?
How should I treat this disease?

In six medical specialties

Oncology
Preventive Care
Urology
Dermatology
Autoimmune
Neuroscience
Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue Growth</td>
<td>Build upon solid hereditary cancer foundation</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td>International Revenue</td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td>&gt;= $50M</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
Critical Success Factors to Achieving Strategic Goals

**STRATEGIC GOALS**

- **>10%** Revenue Growth
- **>30%** Operating Margin
- 7 Products
- **>$50M**
- **>10%** International Revenue

**CRITICAL SUCCESS FACTORS**

- Build upon solid hereditary cancer foundation
- Grow new product volume
- Expand reimbursement coverage for new products
- Increase RNA kit revenue internationally
- Improve profitability with Elevate 2020
Market Leading Hereditary Cancer Test
Three Competitive Advantages Provide Important Differentiation

Lab accuracy:
- 85,000 base pairs with 100% accuracy
- 856 steps using 23 major technology platforms
- 100 proprietary software applications
- Japanese FDA approval of BRACAnalysis CDx

Variant classification:
- 20 years of research; > $100M investment
- >2.5M patients tested; 50k variants identified
- 5 proprietary methods with 99.5% validity
- Proprietary riskScore test

Customer service & support:
- Over 40k ordering physicians annually
- 450 field educators
- Extensive reimbursement support
- Lifetime commitment to patients
Solid Hereditary Cancer Foundation
Stable Pricing and Volume Create Stable Outlook

• Five straight quarter with YoY volume growth
• Exceeded 3% volume growth target in every quarter of FY18
• Successful riskScore™ launch led to accelerating growth in Preventive Care last two quarters
• Stable hereditary cancer pricing expected throughout fiscal year 2019

Key Drivers of Volume Trends

- Competitor Quality Concerns
- Customizable Panels
- U.S. Oncology & ION
- Digital Integration
- riskScore®
Substantial Opportunity for Volume Growth

Highly Underpenetrated in Both Oncology and Preventive Care

U.S. Oncology Market

- Patients Tested by MYGN
- Patients Not Tested (Expanded Criteria)
- Less than 15% penetrated

U.S. Preventive Care Market

- Patients Tested by MYGN
- Patients Not Tested
- Less than 5% penetrated
Critical Success Factors to Achieving Strategic Goals

**Strategic Goals**

- **>10% Revenue Growth**
- **>30% Operating Margin**
- **7 Products**
- **>$50M**
- **>10% International Revenue**

**Critical Success Factors**

- Build upon solid hereditary cancer foundation
- Grow new product volume
- Expand reimbursement coverage for new products
- Increase RNA kit revenue internationally
- Improve profitability with Elevate 2020
## Industry Leading Pipeline

11 Proprietary Products Sold Through Multiple Channels

<table>
<thead>
<tr>
<th>Product</th>
<th>Clinical Question</th>
<th>Global Market Size</th>
<th>Technology</th>
<th>Distribution Channel</th>
</tr>
</thead>
<tbody>
<tr>
<td>myRisk®</td>
<td>Will I get cancer?</td>
<td>$4B 1.5 million patients</td>
<td>28 gene DNA sequencing &gt;80 SNPs + clinical data</td>
<td>Oncology, Women’s Health, Urology</td>
</tr>
<tr>
<td>genesight®</td>
<td>What antidepressant should I take?</td>
<td>$10B 5 million patients</td>
<td>12 genes multiplex PCR proprietary algorithm</td>
<td>Neuroscience, Women’s Health</td>
</tr>
<tr>
<td>Counsyl® Foresight</td>
<td>Is my baby at risk for genetic disease?</td>
<td>$4B 8M patients</td>
<td>&gt;175 gene DNA sequencing</td>
<td>Women’s Health</td>
</tr>
<tr>
<td>Counsyl® Prelude</td>
<td>Does my baby have a chromosomal disorder?</td>
<td>$4B 8M patients</td>
<td>Whole genome sequencing of cfDNA</td>
<td>Women’s Health</td>
</tr>
<tr>
<td>VectraDA</td>
<td>Should I change my RA treatment?</td>
<td>$3B 3 million patients</td>
<td>12 protein markers proprietary algorithm</td>
<td>Autoimmune</td>
</tr>
<tr>
<td>Prolaris®</td>
<td>How aggressively should I treat my prostate cancer?</td>
<td>$1.2B 400,000 patients</td>
<td>46 RNA markers proprietary algorithm</td>
<td>Urology</td>
</tr>
<tr>
<td>EndoPredict®</td>
<td>How aggressively should I treat my breast cancer?</td>
<td>$0.9B 350,000 patients</td>
<td>12 RNA markers proprietary algorithm</td>
<td>Oncology</td>
</tr>
<tr>
<td>myPath®</td>
<td>Is this skin lesion melanoma?</td>
<td>$0.9B 600,000 patients</td>
<td>23 RNA markers proprietary algorithm</td>
<td>Dermatology</td>
</tr>
<tr>
<td>BRACAnalysis®</td>
<td>Should I use a PARP inhibitor to treat my cancer?</td>
<td>$6.0B 1.5 million patients</td>
<td>2 gene DNA sequencing tumor DNA sequencing proprietary algorithm</td>
<td>Oncology</td>
</tr>
</tbody>
</table>
Substantial Diversification in Testing Volumes
>75% of Volume Generated by New Products

FY18*

40% CAGR

≈1,000,000 tests
<25% Hereditary Cancer

FY13

≈180,000 tests
99% Hereditary Cancer

*Includes Counsyl
### Early Stages of Market Adoption

**Significant Opportunity For Continued Growth**

<table>
<thead>
<tr>
<th>Product</th>
<th>TAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary Cancer</td>
<td>$4.0B</td>
</tr>
<tr>
<td>GeneSight</td>
<td>$10.0B</td>
</tr>
<tr>
<td>Vectra DA</td>
<td>$3.0B</td>
</tr>
<tr>
<td>Prolaris</td>
<td>$1.2B</td>
</tr>
<tr>
<td>Foresight</td>
<td>$4.0B</td>
</tr>
<tr>
<td>EndoPredict</td>
<td>$0.9B</td>
</tr>
<tr>
<td>Prelude</td>
<td>$4.0B</td>
</tr>
<tr>
<td>myPath Melanoma</td>
<td>$0.8B</td>
</tr>
<tr>
<td>CDx</td>
<td>$6.0B</td>
</tr>
</tbody>
</table>

---

Rapid Growth Expected in Reproductive Testing Market

60% Increase in U.S. Test Volume Over Next Five Years

U.S. Reproductive Testing Market

NIPS

- Reproductive health market grows at low double-digit rate to **3.5M tests** by FY23

Source: Counsyl, Public filings for SQNM, NTRA, and ILMN
Significant Opportunity for Revenue Synergies

Combined Sales Teams Will Triple Physician Reach in Women’s Health

- Largest genetics sales force in women’s health
- 3x physician reach for Counsyl’s tests
- Potential cross-selling opportunities in hereditary cancer
- 2x the size of the next largest competitor sales force
- 5% increase in market share = $50M in revenue and $25M in EBITDA
Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10% Revenue Growth</td>
<td>Build upon solid hereditary cancer foundation</td>
</tr>
<tr>
<td>&gt;30% Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td>&gt;$50M</td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td>&gt;10% International Revenue</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
Additional Reimbursement is a Growth Multiplier
Fully Reimbursed New Product Revenue is $670 Million

- Hereditary Cancer
  - NCCN Guidelines
  - FY18 Run Rate at Full Reimbursement: $500M
- Foresight
- EndoPredict
  - ACOG Guidelines
  - FY18 Run Rate at Full Reimbursement: $10M
- Prelude
  - ACR Guidelines
  - FY18 Run Rate at Full Reimbursement: $60M
- Prolaris
  - NCCN Guidelines
  - FY18 Run Rate at Full Reimbursement: $70M
- Vectra DA
  - ACR Guidelines
  - Demonstration Studies
  - FY18 Run Rate at Full Reimbursement: $100M
- GeneSight
  - 1,200 Patient RCT
  - Demonstration Studies
  - FY18 Run Rate at Full Reimbursement: $600M
- myPath Melanoma
  - NCCN Guidelines
  - FY18 Run Rate at Full Reimbursement: $6M

U.S. Coverage
GeneSight® Psychotropic
Proprietary Combinatorial Pharmacogenomic Test

Data on 55 antidepressants covering 95% of prescriptions for depression, bipolar disorder, anxiety and schizophrenia.

Use As Directed
Likely well tolerated and efficacious

Moderate Gene-Drug Interaction
Dosing change may improve efficacy/tolerability

Significant Gene-Drug Interaction
Poorly tolerated and/or efficacy concerns

331,776 unique GeneSight report genetic combinations and medication recommendations
RCT Results Provide Clinical Validity For GeneSight

50% Increase in Remission and 30% Increase in Response

Outcome Measures at Week 8

- **Remission (HAMD-17)**
  - GeneSight: 50% improvement in remission (p=0.007)
  - TAU: 14% improvement in symptoms (p=0.107)
  - n=560

- **Response (HAMD-17)**
  - GeneSight: 50% improvement in remission (p=0.013)
  - TAU: 30% improvement in response (p=0.007)
  - n=607

- **Symptom Improvement (HAMD-17)**
  - GeneSight: 50% improvement in remission (p=0.007)
  - TAU: 30% improvement in response (p=0.007)
  - n=560

Symptom Improvement Stratified By Entering Medication

Patients Who Entered On Non-Congruent Medications Saw Biggest Improvement

GeneSight vs. TAU
Relative Symptom Improvement at 8 weeks
stratified by worst entering medication

STRATIFICATION AT BASELINE

- Green: 5%
- Yellow: 12%
- Red: 33%
- Total improvement: 49%
Symptom Improvement Stratified By Entering Medication

Patients Who Entered On Non-Congruent Medications Saw Biggest Improvement

**Remission**
- Percent of Patients: 153% Improvement (p=0.0067)
- Baseline: 8.5%
- Week 8: 21.5%

**Response**
- Percent of Patients: 71% Improvement (p=0.0364)
- Baseline: 16.7%
- Week 8: 28.5%

**Symptom Improvement**
- Percent Decrease in HAM-D17: 59% Improvement (p=0.0018)
- Baseline: 21.1%
- Week 8: 33.5%
GeneSight Health Economic Data
Real World Clinical Studies Show Rapid Pay Back For Insurers

MORE THAN $1,000
Drug Spend Savings¹

MORE THAN $1,500
Healthcare Savings²

UP TO $775
Productivity Savings²

MORE THAN $3,275
Potential Savings Annually

Payer

Employer
Critical Success Factors to Achieving Strategic Goals

**STRATEGIC GOALS**

- **>10%** Revenue Growth
- **>30%** Operating Margin
- **7 Products**
- **>$50M**
- **>10%** International Revenue

**CRITICAL SUCCESS FACTORS**

- Build upon solid hereditary cancer foundation
- Grow new product volume
- Expand reimbursement coverage for new products
- Increase RNA kit revenue internationally
- Improve profitability with Elevate 2020
### International Growth Focused in Major Geographies

*Kit Products Appeal to Existing Business Models*

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>KITS</th>
<th>REFERENCE TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct Sales:</strong></td>
<td>DNA (multiple platforms):</td>
<td>Companion Diagnostics</td>
</tr>
<tr>
<td>EU5 + Canada</td>
<td>• EndoPredict</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prolaris</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPath Melanoma</td>
<td></td>
</tr>
<tr>
<td><strong>Distributor</strong></td>
<td>RNA (platform partner):</td>
<td><strong>myRisk</strong></td>
</tr>
<tr>
<td>China, Japan, Brazil,</td>
<td>• EndoPredict</td>
<td></td>
</tr>
<tr>
<td>and others</td>
<td>• Prolaris</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPath Melanoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Protein (platform partner):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Vectra DA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPath Bipolar</td>
<td></td>
</tr>
</tbody>
</table>
### Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&gt;10% Revenue Growth</strong></td>
<td><strong>Build upon solid hereditary cancer foundation</strong></td>
</tr>
<tr>
<td><strong>&gt;30% Operating Margin</strong></td>
<td><strong>Grow new product volume</strong></td>
</tr>
<tr>
<td>7 Products</td>
<td><strong>Expand reimbursement coverage for new products</strong></td>
</tr>
<tr>
<td><strong>&gt;$50M</strong></td>
<td><strong>Increase RNA kit revenue internationally</strong></td>
</tr>
<tr>
<td><strong>&gt;10% International Revenue</strong></td>
<td><strong>Improve profitability with Elevate 2020</strong></td>
</tr>
</tbody>
</table>
Elevate 2020 Outperforming Expectations
On Track to Achieve >$50M in Incremental Operating Profit by FY20

FY18:
16 projects identified
>$17M in cost savings

FY19:
15 projects identified
$24M in cost savings

FY20 and beyond:
Additional project evaluations
Additional cost savings

Goal:
$50M in incremental operating profit by FY20
Financial Outlook
Comparison of Adjusted EPS and FCF/Share

Adjusted EPS Significantly Understates Cash Earnings Power

TTM FCF/Share = $1.72
Additional Reimbursement Transformative
With Full Reimbursement FY18 Revenue >$1.4B, Operating Margins >40%

- Revenue >$1.4B
- >40% adjusted operating margin
- >$450 million in free cash flow
- >$5.00 per share in adjusted EPS
## Uses of Cash

<table>
<thead>
<tr>
<th>Uses of Cash</th>
<th>Current Focus</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R&amp;D</strong></td>
<td>10% of revenue</td>
<td>Invest in late-stage reimbursement studies</td>
</tr>
<tr>
<td><strong>M&amp;A</strong></td>
<td>Integration of Counsyl acquisition</td>
<td>Assess opportunities that fit 4in6 strategy with potential for near-term accretion</td>
</tr>
<tr>
<td><strong>Debt Repayment</strong></td>
<td>$69M prior to Counsyl acquisition</td>
<td>Reduce with excess free cash flow</td>
</tr>
<tr>
<td><strong>Share Repurchase</strong></td>
<td>$174M authorized</td>
<td>Opportunistic open market purchases</td>
</tr>
</tbody>
</table>
Worldwide Leader in Personalized Medicine

• We are entering the golden age for personalized medicine
• Molecular diagnostics are the keystone for improving patient outcomes while eliminating waste in healthcare spending
• Myriad is the pioneer of “research-based” and “education-centric” business model for molecular diagnostics
• We are the best positioned company to lead this revolution in healthcare